Shenzhen Boyin Biotechnology

Shenzhen Boyin Biotechnology Co., Ltd., also known as PAM2L Biotechnologies, was established in March 2021 by Dr. Zhong Chao and his university classmate, Cui Junfeng. The company operates at the intersection of synthetic biology and machine learning, focusing on developing and producing bio-based materials. The firm targets high-value markets, directing its efforts toward protein and polysaccharide raw materials for application in pharmaceuticals, medical aesthetics, cosmetics, and food.

Dr. Zhong Chao is a recognized scientist in synthetic biology who studied at the Massachusetts Institute of Technology (MIT) and later established the Center for Materials Synthetic Biology at the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences. Co-founder and CEO Cui Junfeng brings extensive industry experience from roles at MicroPort, 3M, Adisseo, and Giant Medical, with expertise spanning R&D, production, supply chain, and commercialization. This leadership combines deep scientific knowledge with practical industrial application. The company's advisory team includes scientists and clinical experts from institutions like MIT, Cornell University, and several major hospitals.

Boyin Biotechnology's business model is centered on creating innovative biomaterials through a technology platform driven by both synthetic biology and artificial intelligence. This dual-core approach is designed to produce novel, low-cost, and sustainable materials. The company has successfully industrialized several bioactive molecules, including recombinant mussel adhesive protein and CA viscous polysaccharides. Their product development is end-to-end, covering everything from material design and biosynthesis to application development. A key product, recombinant mussel adhesive protein, offers significant potential for repairing skin and mucous membranes. For instance, the company states that the protein produced per liter of fermentation broth is equivalent to that from millions of mussels, offering a sustainable and cost-effective alternative. The company has secured nearly 200 million yuan in financing from investors such as Wuyuan Capital, Fuhua Capital, and Co-Stone Capital to upgrade its R&D platform and expand production capacity.

Keywords: synthetic biology, biomaterials, machine learning, protein raw materials, polysaccharide raw materials, medical aesthetics, pharmaceuticals, cosmetics, food additives, Dr. Zhong Chao, Cui Junfeng, mussel adhesive protein, bioactive molecules, BT-IT dual-driven, life sciences, venture capital-backed, Shenzhen, biomanufacturing, sustainable materials